Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mallinckrodt plc

http://www.mallinckrodt.com

Latest From Mallinckrodt plc

US FDA Loses Orphan Exclusivity Case While HHS Wins Dismissal Of Pfizer Kickback Complaint

In rare loss for FDA, appeals court reverses district court decision tossing Catalyst’s suit over Orphan Drug Act, saying deference should not have been granted to agency’s interpretation. District court finds it is too early to rule on one Pfizer charity co-pay program but backs broad reading of Anti-Kickback Statute.

Rare Diseases Pricing Strategies

Premature PRV: US FDA Mistakenly Announces Voucher Award For Enzyvant Ahead Of Approval

Congenital athymia treatment Rethymic (RVT-802) is still under FDA review, with an 8 October user fee goal date, but FDA announced the regenerative medicine product had earned a rare pediatric disease priority review voucher; agency says the notice was published in error and will be withdrawn.

Rare Diseases Pediatrics

Attralus Raises $116m To Advance Amyloidosis-Clearing Pipeline

The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.

Financing Platform Technologies

US And EU Approvals In First Half 2021 Underscore US-First Orientation Of Novel Drug Development

Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.

Approvals Review Pathway
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Aspect Medical Systems, Inc.
    • BÂRRX Medical, Inc.
    • Cadence Pharmaceuticals, Inc.
    • CNS Therapeutics, Inc.
    • ev3 Inc.
    • Given Imaging Ltd.
    • Ikaria Holdings, Inc.
    • InfaCare Pharmaceutical Corporation
    • INO Therapeutics, LLC
    • Mallinckrodt Inc.
    • Mallinckrodt Pharmaceuticals
    • Micro Therapeutics, Inc.
    • Nellcor Puritan Bennett, Inc.
    • Ocera Therapeutics Inc. (OCRX)
    • Oridion Systems Ltd.
    • Questcor Pharmaceuticals, Inc.
    • Somanetics Corp.
    • Sonorant Inc.
    • SpecGx Inc.
    • Sucampo Pharmaceuticals, Inc.(SCMP)
    • VNUS Medical Technologies
    • Stratatech Corporation
    • Tranzyme Pharma
UsernamePublicRestriction

Register